Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis

HSP90 Inhibitors: Current Development and Potential in Cancer Therapy

(2013) Katerina Sidera et al.   Recent Patents on Anti-Cancer Drug Discovery

Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis

(2012) Christian Beyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis

(2012) Nicole Reich et al.   ANNALS OF THE RHEUMATIC DISEASES

Autophagy regulates TNFα-mediated joint destruction in experimental arthritis

(2012) Neng-Yu Lin et al.   ANNALS OF THE RHEUMATIC DISEASES

β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis

(2012) Christian Beyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis

(2012) Marlene Krämer et al.   ANNALS OF THE RHEUMATIC DISEASES

Tyrosine kinase signaling in fibrotic disorders

(2012) Christian Beyer et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease

(2012) P. Zerr et al.   BLOOD

Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics

(2012) Armin Haupt et al.   BMC CANCER

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

(2012) Shiro Soga et al.   CURRENT PHARMACEUTICAL DESIGN

Heat shock proteins in cancer: targeting the ‘chaperones’

(2012) Z Nahleh et al.   Future Medicinal Chemistry

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

(2012) Oliver Weigert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

(2012) Alfiya Akhmetshina et al.   Nature Communications

The transcription factor JunD mediates transforming growth factor  -induced fibroblast activation and fibrosis in systemic sclerosis

(2011) K. Palumbo et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis

(2011) Clara Dees et al.   ARTHRITIS AND RHEUMATISM

Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis

(2011) Jérôme Avouac et al.   ARTHRITIS AND RHEUMATISM

Platelet-derived serotonin links vascular disease and tissue fibrosis

(2011) Clara Dees et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Animal models of systemic sclerosis: Prospects and limitations

(2010) Christian Beyer et al.   ARTHRITIS AND RHEUMATISM

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

(2010) Alessandro Allegra et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Scleroderma

(2009) Armando Gabrielli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis

(2008) Catherine Skhirtladze et al.   ARTHRITIS AND RHEUMATISM

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

(2008) Alfiya Akhmetshina et al.   FASEB JOURNAL

Critical regulation of TGF  signaling by Hsp90

(2008) K. H. Wrighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA